Pitfalls in patenting academic CAR-T cells therapy.
Cătălin ConstantinescuRoxana ConstantinescuJon Thor BergthorssonVictor GreiffAlina TanaseAnca ColitaDiana GuleiCiprian TomuleasaPublished in: Expert opinion on therapeutic patents (2023)
There is no one-size-fits-all solution in this matter and the medical evolution of this therapy will certainly bring out even more challenges. Comprehensive knowledge of the intellectual property, exposure to potential litigation, growing competition, and the high price of therapy, are strikingly relevant in the broader landscape. Future endeavors would be to take steps towards the harmonization of the CAR-T patenting procedure.